Vis enkel innførsel

dc.contributor.authorDankel, Dorothy Janeeng
dc.contributor.authorRoland, Kenneth L.eng
dc.contributor.authorFisher, Michaeleng
dc.contributor.authorBrenneman, Kareneng
dc.contributor.authorDelgado Alemán, Anaeng
dc.contributor.authorSantander, Javiereng
dc.contributor.authorBaek, Chang-Hoeng
dc.contributor.authorClark-Curtiss, Josephineeng
dc.contributor.authorStrand, Rogereng
dc.contributor.authorCurtiss, Roy IIIeng
dc.date.accessioned2014-12-23T07:29:21Z
dc.date.available2014-12-23T07:29:21Z
dc.date.issued2014-07-10eng
dc.identifier.issn1871-4757
dc.identifier.urihttps://hdl.handle.net/1956/9017
dc.description.abstractResearchers have iterated that the future of synthetic biology and biotechnology lies in novel consumer applications of crossing biology with engineering. However, if the new biology’s future is to be sustainable, early and serious efforts must be made towards social sustainability. Therefore, the crux of new applications of synthetic biology and biotechnology is public understanding and acceptance. The RASVaccine is a novel recombinant design not found in nature that re-engineers a common bacteria (Salmonella) to produce a strong immune response in humans. Synthesis of the RASVaccine has the potential to improve public health as an inexpensive, non-injectable product. But how can scientists move forward to create a dialogue of creating a ‘common sense’ of this new technology in order to promote social sustainability? This paper delves into public issues raised around these novel technologies and uses the RASVaccine as an example of meeting the public with a common sense of its possibilities and limitations.en_US
dc.language.isoengeng
dc.publisherSpringereng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0eng
dc.subjectBiotechnologyeng
dc.subjectEthicseng
dc.subjectLegal issueseng
dc.subjectSocial aspectseng
dc.subjectSocietyeng
dc.subjectSocietal valueseng
dc.subjectTrusteng
dc.subjectVaccineeng
dc.subjectValueseng
dc.titleMaking common sense of vaccines: an example of discussing the recombinant attenuated salmonella vaccine with the publiceng
dc.typeJournal articleeng
dc.typePeer reviewedeng
dc.date.updated2014-12-23T07:23:46Z
dc.description.versionpublishedVersion
dc.rights.holderCopyright 2014 The Authors
dc.identifier.doihttps://doi.org/10.1007/s11569-014-0198-6
dc.identifier.cristin1163241
dc.source.journalNanoEthics
dc.source.408
dc.source.142
dc.source.pagenumber179-185


Tilhørende fil(er)

Thumbnail
Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY